Figitumumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Figitumumab
Accession Number
DB11685
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Figitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
CP-751,871 / CP-751871
Categories
UNII
VE267FC2UB
CAS number
943453-46-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Figitumumab.Approved
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Figitumumab.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Figitumumab.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Figitumumab.Investigational
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Figitumumab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Figitumumab.Approved
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Figitumumab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Figitumumab.Investigational
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Figitumumab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Figitumumab.Approved, Withdrawn
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Figitumumab.Approved
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Figitumumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Figitumumab.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Figitumumab.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Figitumumab.Approved, Investigational
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Figitumumab.Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Figitumumab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Figitumumab.Approved, Investigational
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Figitumumab.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Figitumumab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Figitumumab.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Figitumumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Figitumumab.Investigational
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Figitumumab.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Figitumumab.Approved
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Figitumumab.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911227
Wikipedia
Figitumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Non-Hematologic Malignancies1
1CompletedTreatmentEwing's Sarcoma (ES)1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentSarcomas / Tumors, Solid1
1TerminatedBasic ScienceHealthy Volunteers1
1TerminatedTreatmentAdvanced Solid Tumors / Cancer, Advanced1
1TerminatedTreatmentNeoplasms, Breast / Neoplasms, Colorectal / Neoplasms, Lung / Prostatic Neoplasms / Sarcomas1
1WithdrawnTreatmentCancer, Breast1
1, 2CompletedTreatmentEwing's Sarcoma Family of Tumors1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentProstatic Neoplasms1
2TerminatedTreatmentHead and Neck Carcinoma1
2TerminatedTreatmentNeoplasms, Breast1
2TerminatedTreatmentSmall Cell Lung Carcinoma1
2WithdrawnTreatmentCancer, Breast1
3TerminatedTreatmentCarcinoma, Adenosquamous Cell / Carcinoma, Large Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
3TerminatedTreatmentCarcinoma, Adenosquamous / Carcinoma, Large Cell / Lung Cancer Non-Small Cell Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
3WithdrawnTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:39 / Updated on August 02, 2018 06:28